Genetic Engineering News -- Index Ventures has pledged to provide up to a €10 million (about $14 million) investment in Mind-NRG, a newly incorporated Swiss CNS therapeutics firm. The new company is focused on the development of a peptidic neurotrophic factor candidate NRG-101, which it claims has disease-modifying potential and can cross the blood-brain barrier by receptor-mediated transport to reach its target. NRG-101 has been acquired from German systems biology firm ProteoSys, in return for Mind-NRG equity.
